Science Explorer Back to mapMap
Discussion
Institution · BioBridges (United States)

Most cited papers from BioBridges (United States)

BioBridges (United States)

What are the most cited papers from BioBridges (United States)?

The most cited paper from BioBridges (United States) is "Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström's macroglobulinemia" (Steven Peter Treon, Christina K. Tripsas, Kirsten Meid et al., 2014), with 179 citations. Next come "Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia" (148) and "Machine-learning, MRI bone shape and important clinical outcomes in osteoarthritis: data from the Osteoarthritis Initiative" (128).

Showing 29 of 29 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström's macroglobulinemia Steven Peter Treon, Christina K. Tripsas, Kirsten Meid et al. · Blood Open access 24 May 2014 179
2 Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia Steven Peter Treon, Andrew Robert Branagan, Leukothea Ioakimidis et al. · Blood Open access 18 Nov 2008 148
3 Machine-learning, MRI bone shape and important clinical outcomes in osteoarthritis: data from the Osteoarthritis Initiative M.A. Bowes, Katherine A. Kacena, Oras Alabas et al. · Annals of the Rheumatic Diseases Open access 13 Nov 2020 128
4 A prospective multicenter observational study of cell-mediated immunity as a predictor for cytomegalovirus infection in kidney transplant recipients Deepali Kumar, Peter V Chin-Hong, Liise K. Kayler et al. · American Journal of Transplantation Open access 15 Feb 2019 124
5 Maintenance Rituximab is associated with improved clinical outcome in rituximab naïve patients with Waldenstrom Macroglobulinaemia who respond to a rituximab‐containing regimen Steven Peter Treon, Christina Hanzis, Robert J. Manning et al. · British Journal of Haematology 25 May 2011 101
6 BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant EGFR Mutations in Non–Small Cell Lung Cancer Sun Min Lim, Toshio Fujino, Chulwon Kim et al. · Clinical Cancer Research Open access 30 May 2023 81
7 Attainment of complete/very good partial response following rituximab‐based therapy is an important determinant to progression‐free survival, and is impacted by polymorphisms in FCGR3A in Waldenstrom macroglobulinaemia Steven Peter Treon, Guang Yang, Christine Hanzis et al. · British Journal of Haematology 12 May 2011 74
8 Comparative Outcomes Following CP-R, CVP-R, and CHOP-R in Waldenström's Macroglobulinemia Leukothea Ioakimidis, Christopher J. Patterson, Zachary R. Hunter et al. · Clinical Lymphoma & Myeloma Mar 2009 69
9 Differentiating Familial Chylomicronemia Syndrome From Multifactorial Severe Hypertriglyceridemia by Clinical Profiles Louis St L O'Dea, James E. MacDougall, Veronica J. Alexander et al. · Journal of the Endocrine Society Open access 11 Oct 2019 64
10 Qutenza (Capsaicin) 8% Patch Onset and Duration of Response and Effects of Multiple Treatments in Neuropathic Pain Patients Joy Mou, Florence C. Paillard, Barry Turnbull et al. · Clinical Journal of Pain 12 Jun 2013 53
11 Efficacy of the nanoparticle–drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I–IIa clinical trial Stephen J. O’Keefe, Jean H. Hoffman-Censits, Roger B. Cohen et al. · Annals of Oncology Open access 25 Jul 2016 52
12 Predictors of Response in Patients With Postherpetic Neuralgia and HIV-Associated Neuropathy Treated With the 8% Capsaicin Patch (Qutenza) Nathaniel P. Katz, Joy Mou, Florence C. Paillard et al. · Clinical Journal of Pain 12 Dec 2014 37
13 Familial Disease Predisposition Impacts Treatment Outcome in Patients With Waldenström Macroglobulinemia Steven Peter Treon, Christina K. Tripsas, Christina Hanzis et al. · Clinical Lymphoma Myeloma & Leukemia 17 Oct 2012 27
14 Utility of the T-SPOT®.TB test's borderline category to increase test resolution for results around the cut-off point Karen Rego, Kristen Pereira, James E. MacDougall et al. · Tuberculosis Open access 18 Dec 2017 21
15 Inhibition of αvβ6 Promotes Acute Renal Allograft Rejection in Nonhuman Primates Denise J. Lo, Alton B. Farris, Minjung Song et al. · American Journal of Transplantation Open access 2 Oct 2013 21
16 Biofuels, science and society H. Chris Greenwell, Meredith Lloyd-Evans, Clare Wenner · Interface Focus Open access 21 Dec 2012 15
17 Comparative Response Assessment by Serum Immunoglobulin M M-Protein and Total Serum Immunoglobulin M After Treatment of Patients With Waldenström Macroglobulinemia Christina K. Tripsas, Christopher J. Patterson, Sacha Uljon et al. · Clinical Lymphoma Myeloma & Leukemia Apr 2013 13
18 Identification of robust predictors for ibrutinib response by multiomics in MYD88-mutated Waldenström macroglobulinemia Kris Richardson, Jorge J. Castillo, Shayna Sarosiek et al. · Blood Advances Open access 18 Jan 2024 4
19 Treatment with a Bortezomib-Containing Regimen Is Associated with Better Therapeutic Outcomes in Patients with Waldenstrom's Macroglobulinemia Who Have Familial Disease Predisposition Steven Peter Treon, Zachary R. Hunter, Christina Hanzis et al. · Blood 18 Nov 2011 3
20 Maintenance Rituximab Is Associated with Improved Progression Free and Overall Survival in Waldenstrom's Macroglobulinemia. Steven Peter Treon, Christina Hanzis, Robert R Manning et al. · Blood 20 Nov 2009 1
21 Progression Free Survival Is Predicated by Categorical Response, and Supports the Attainment of VGPR/CR as An Objective for Long Term Disease Control in Waldenstrom's Macroglobulinemia. Steven Peter Treon, Thea Ioakimidis, Christina Hanzis et al. · Blood 20 Nov 2009 1
22 SPACE EIKONOMETRY IN ANISEIKONIA Robert E. Bannon · American journal of optometry and archives of American Academy of Optometry Feb 1953 0
23 SPACE PERCEPTION—SOME PHYSIOLOGICAL AND PSYCHOLOGICAL ASPECTS Robert E. Bannon · American journal of optometry and archives of American Academy of Optometry Oct 1952 0
24 THE EFFECT OF ULTRAVIOLET ON THE HUMAN EYE Paul A. Boeder · American journal of optometry and archives of American Academy of Optometry Sep 1950 0
25 INDUSTRIAL VISUAL SCREENING W. T. Cameron · American journal of optometry and archives of American Academy of Optometry Apr 1951 0
26 SYMPTOMS AND CASE HISTORY—THE PATIENT AS A PERSON Robert E. Bannon · American journal of optometry and archives of American Academy of Optometry Jun 1952 0
27 CO216 Safety and Efficacy of Antibody Drug Conjugate (ADCs) in Pretreated Locally Advanced/Metastatic (LA/m) Triple-Negative Breast Cancer (TNBC): Systematic Literature Review (SLR) Patricia Dorling, Shalini Bagga, Vaneet Kaur Khurana et al. · Value in Health Review Dec 2025 0
28 CO90 Efficacy and Safety of Antibody-Drug Conjugates (ADCs) in Pretreated Locally Advanced/Metastatic (LA/m) Non-Small Cell Lung Cancer (NSCLC): A Systematic Literature Review (SLR) Patricia Dorling, Shalini Bagga, V Khurana et al. · Value in Health Review Dec 2025 0
29 A novel structural status assessment of oa is strongly associated with all patient important outcomes - an mri study of 9,433 knees from the osteoarthritis initiative M.A. Bowes, Katherine A. Kacena, Oras Alabas et al. · Osteoarthritis and Cartilage Open access Apr 2020 0

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.